Pulmonary chronic graft-versus-host disease (p-CGVHD) following allogeneic HSCT is devastating with limited proven treatments. Although sporadically associated with pulmonary toxicity, the proteasome inhibitor bortezomib may be efficacious in p-CGVHD. We sought to establish safety and tolerability of bortezomib in pilot, open-label trial of patients with p-CGVHD. The primary endpoint was adverse events. Efficacy was assessed by comparing FEV1 decline prior to p-CGVHD diagnosis to during the bortezomib treatment period. The impact on pulmonary function testing of prior long-term bortezomib treatment in multiple myeloma (MM) patients was also assessed as a safety analysis. Seventeen patients enrolled in the pilot study with a mean time to p-CGVHD diagnosis of 3.36 years (±1.88 years). Bortezomib was well tolerated without early dropouts. The median FEV1 decline prior to the diagnosis of p-CGVHD was −1.06%/month (−5.36, −0.33) and during treatment was −0.25%/month (−9.42, 3.52). In the safety study, there was no significant difference in any PFT parameter between 73 patients who received bortezomib and 68 patients who did not for MM. Thus, we conclude that bortezomib has acceptable safety and tolerability in patients with compromised pulmonary function. The efficacy of proteosomal inhibition should be assessed in a large trial of chronic p-CGVHD patients.
Introduction
Approximately 10,000 allogeneic hematopoietic stem cell transplants (HSCTs) are performed annually for various indications in the United States. Chronic graft-versus-host disease (CGVHD) is the most common late non-infectious pulmonary complication following allogeneic HSCT [1] . The exact incidence of pulmonary CGVHD is not clear but may be as high as 30% [2] . Risk factors for pulmonary CGVHD include age, antecedent obstructive airways disease, and viral infections [1] . It is characterized physiologically by progressive irreversible airflow obstruction [2] and pathologically by luminal occlusion of the distal airways due to progressive scarring, referred to as obliterative bronchiolitis [3] . Prognosis of pulmonary CGVHD after HSCT is dismal, there is no consensus on optimal therapy and there are no therapies proven to improve survival [4] .
Development of pulmonary CGVHD is thought to be initiated by an immune cell-mediated distal airway injury [5, 6] and subsequent aberrant repair response. It is likely that multiple factors play a role in its pathogenesis including aberrant transforming growth factor-beta 1 (TGF-β1) expression, defective negative selection of T cells, autoantibody production, and deficiency of T-regulatory cells [7] . Evidence for a central role for TGF-β1 comes from both animal models and human studies. Specifically inhibition of TGF-β1 in an animal model of allogeneic HSCT decreased the severity of CGVHD and smad-3 deficiency (a critical downstream mediator of TGF-β1 signaling) prevents bronchiolits obliterans ( BO) in an animal model [8, 9] . In human studies, gene expression analysis of immune cells from HSCT patients suggests activation of TGF-β1 pathway is associated with CGVHD and TGF-β1, and has been detected in alveolar fluid of pulmonary CGHVD patients [10, 11] .
We have published data that bortezomib inhibits TGF-β1 signaling in vitro and protects against lung injury/fibrosis in the TGF-β1-mediated intratracheal bleomycin mouse model, as well as in a mouse model for skin fibrosis [12] . This is consistent with other data in the literature that proteasome inhibition can prevent the development of fibrosis [13, 14] . In addition, there are reports showing efficacy of bortezomib in non-pulmonary CGVHD [15, 16] . However, there are also reports of pulmonary toxicity following bortezomib administration [17] [18] [19] .
In order to provide a rationale for testing bortezomib in a pivotal trial of pulmonary CGVHD, we conducted two analyses in order to assess the pulmonary safety of bortezomib. In the first analysis, we performed a prospective pilot study to assess the safety and efficacy of bortezomib in patients with pulmonary CGVHD. We also assessed the impact of prior bortezomib therapy on pulmonary function in myeloma patients awaiting HSCT before starting the pilot study in order to ensure adequate safety.
Methods

Patient population
The pilot study was a prospective open-label trial to test the safety and efficacy of bortezomib in patients with pulmonary CGVHD after having undergone allogeneic HSCT. Subjects were recruited from the HSCT Program of Northwestern Memorial Hospital. The key inclusion criteria were: age 18-70 years, underlying malignancy in remission, >100 days post-HSCT, an absolute decrease of ≥12% in forced expiratory volume in one second (FEV1) from the pre-transplant baseline and FEV1/forced vital capacity (FVC) ratio <0.8, and no evidence of active infection. The key exclusion criteria were platelets <50 × 10 9 /L, absolute neutrophil count <1 × 10 9 /L, creatinine clearance <20 mL/ min, grade 2 peripheral neuropathy, myocardial infarction within 6 months prior to enrollment, or New York Heart Association (NYHA) Class III or IV heart failure (for full inclusion and exclusion criteria, see supplementary figure 1) . The patients were treated subcutaneously with bortezomib 1.3 mg/m 2 weekly for 4 weeks, following which there was a 2-week drug holiday and then a second 4-week cycle was administered. The primary efficacy endpoint was change in percent predicted FEV1. The study was approved by the local IRB at Northwestern University (study ID-STU00022160. Informed consent is provided as a supplementary file).
For the retrospective safety analysis, we collected pulmonary function data on 141 patients who had undergone autologous HSCT for multiple myeloma (MM) over the preceding 2-year period. They separated them into those who had received bortezomib as part of the induction regimen (usually with dexamethasone; with or without lenalidomide) and those who had not received bortezomib (usually with lenalidomide and dexamethasone). We compared their pulmonary function testing (PFT) parameters prior to HSCT.
Statistics
Data were collected and stored on Excel spreadsheet by the clinical research staff, under consultation with study statistician. Means, standard deviations, and medians were computed and reported to the primary investigator (PI) by study statistician, who performed all of the analyses. Slopes were computed by dividing difference in FEV1 by time in months. Since post-treatment period is much shorter than the pre-treatment period, Fig. 1 is an idealized presentation of change. Graphics were done in R and the stat analysis in Stata.
Results
Demographics, SCT indication, and lung function at enrollment
Seventeen patients were enrolled in the study. The mean age was 45 years ± 3 years, 76% were male and 82% Caucasian. Of patients enrolled, the most common indication for SCT was acute myelogenous leukemia (AML) at 35%, with Bortezomib attenuates FEV1 decline after diagnosis of pulmonary GVHD. Pulmonary function testing was performed prior to allogeneic stem cell transplantation (pre-SCT) and prior to beginning bortezomib and after completing the last dose of bortezomib. Shown are the individual trajectories of FEV1 from the time of SCT to beginning bortezomib and from beginning bortezomib to the end of the study. Since the treatment period is much shorter than the pretreatment period, the graph represents idealized times lymphoma, chronic myelogenous leukemia (CML) and MM being less common. Additional specifics on SCT characteristics are detailed in Table 1 . The mean FEV1 and FVC prior to SCT were as 90% ± 17 and 89% ± 18, respectively. At time of study entry, the mean FEV1 and FVC were 47% ± 15% and 60% ± 15% predicted. Patients enrolled into the study on the average 3.36 ± 1.88 years after SCT. All the patients had evidence of CGVHD in other organs, the majority of whom had evidence of extensive GVHD, and were on immunosuppressive agents (Supplementary Table 1 ). The most common respiratory symptoms were dyspnea and cough.
Tolerability and safety analysis
Patients were scheduled to receive 1.3 mg/m 2 bortezomib on days 1, 8, 15, 22, 35, 42, 49 , and 56. Thus, patients could receive a maximum of 8 bortezomib doses over a period of 10 weeks (two 4-week cycles with an intervening 2-week rest). Sixteen out of 17 patients (94%) received at least 6 doses and 13 (76%) received all 8 doses. Overall, treatment was tolerated well with no early dropouts. There were a total of 67 adverse events reported during the study, none of which were severe. The majority of adverse events were grade 1 and 2 and were categorized to general and gastrointestinal systems. The incidence of neurologic and pulmonary adverse events was low. There were two pulmonary AE's, cough (grade 2), and flu-like syndrome (grade 1). The low incidence of pulmonary adverse events is especially noteworthy since all the patients had severely compromised FEV1 at the start of the study (Tables 2 and 3) .
We performed an additional safety analysis on a separate cohort of patients. We conducted a retrospective study to examine pulmonary function data on 141 MM patients prior to HSCT. Seventy-three patients had received prolonged treatment with bortezomib prior to testing while 68 patients had not received bortezomib prior to HSCT. There was no significant difference in any measured PFT parameter between the cohort that received bortezomib and the cohort that had not as part of their MM treatment (Fig. 2 ). This suggests that there is no predictable added risk to pulmonary function with bortezomib used compared with other chemotherapies used for MM.
Primary efficacy outcomes
All patients had PFTs performed prior to HSCT and at the time of diagnosis of pulmonary CGVHD. During the study, each patient had spirometry tested up to six times from screening to the end of the study. This allowed us to estimate the slope of % FEV1 change from SCT to pulmonary GVHD diagnosis, as well as over the duration of the nearly 3-month study. The median % FEV1 slope for the whole cohort prior to the diagnosis of pulmonary GVHD was −1.06% with range (−5.36, −0.33) and the mean was −1.54%/month ± 1.31/month. The median % FEV1 slope was −0.25%/month with range (−9.42, 3.52) and the mean FEV1 slope during the treatment phase for the cohort was −0.96%/month ± −2.98/month. We then calculated individual FEV1 slopes for each patient prior to GVHD diagnosis and during the study period. As expected, each patient had a negative FEV1 slope prior to GVHD diagnosis. Of 17 patients in the study, 8 had a % FEV1 slope of >0 indicating their lung function improved during the treatment phase (Fig. 1) . We then performed a second analysis in which we stratified our cohort based on an FEV1 slope greater than or equal to −0.30%/month or less than −0.30%/month. This threshold was based on previous data suggesting that patients with an FEV1 decline less than this threshold had improved survival [20] . Using this threshold, 9 out of 17 patients had an FEV1 decline less than −0.30%/month and 8 patients more than −0.30%/month (Fig. 1) . Finally, in 11 out of 17 patients their FEV1 decline was slower during the treatment phase than prior to the diagnosis of pulmonary GVHD (Fig. 1 ).
Secondary outcomes
We also looked at SF-36 as a secondary outcome measures.
Comparing from the start of the trial to the end, there was no significant change in any component in the SF-36 (data not shown).
Discussion
In this report, we present data from a single-center pilot study, which shows that bortezomib, a proteasome inhibitor, is safe and well tolerated in patients with pulmonary CGVHD. We also present data from a retrospective analysis that bortezomib does not impact pulmonary function in MM patients treated with bortezomib for an extended period of time. Further, although our pilot clinical trial was not powered for efficacy, our data suggest that bortezomib may be efficacious in this patient population. There are multiple strengths of our completed pilot trial. These include a sound pathophysiologic rationale, prospective recruitment of patients with well-defined inclusion and exclusion criteria and validated clinical endpoints. Further the use of bortezomib for pulmonary CGVHD is novel and our study is the first to report the use bortezomib in patients with known compromised pulmonary function. Finally, we used FEV1 decline as an efficacy measure in order to more accurately assess the impact of bortezomib on the natural history of pulmonary CGVHD. As there can be significant normal variability in FEV1 [21] , calculating Fig. 2 Bortezomib use is not associated with loss of pulmonary function. In total, 141 multiple myeloma patients prior to autologous HSCT had full pulmonary function testing performed. Seventy-three patients had received multiple doses of bortezomib prior to testing, while 68 patients had not received bortezomib. There was no significant difference in any measured PFT parameter between the cohort that received bortezomib and the cohort that had not FEV1 slopes can correct for this variability and potentially allows for a more precise assessment of the impact of pulmonary targeted therapy. Development of pulmonary CGVHD is a devastating complication following HSCT with a 5-year survival of as low as 13% [4] . There are multiple treatment regimens that have been reported to show efficacy, but most of these studies are limited in size and difficult to compare due to differences in trial design, small numbers of patients, inconsistent inclusion/exclusion criteria, and varied endpoints [20, [22] [23] [24] . Thus, there is no consensus on the optimal treatment regimen to improve lung function and no regimen has ever been shown to improve survival. Clearly new treatment options are needed and bortezomib offers a novel option for pulmonary CGVHD.
There are sound pathophysiologic reasons to consider bortezomib in this patient population. Previous work has implicated aberrant TGF-β1 expression, defective negative selection of T cells, auto-antibody production, and deficiency of T-regulatory cells [7] . In addition, inhibiting TGF-β signaling has been shown to improve outcomes in animal models of pulmonary CGVHD. Along with others, we have previously shown that proteasomal inhibition generally and bortezomib specifically inhibits TGF-β signaling [25] [26] [27] . In addition to its ability to inhibit TGF-β signaling, bortezomib also has significant immunomodulatory effects including inhibition of T and B lymphocytes, which are important targets in CGVHD [28] . For these reasons, we chose to test bortezomib in this patient population.
Our pilot trial data suggest that bortezomib was generally well tolerated without any grade 4 or 5 toxicity. The majority of patients received all their doses and there were no premature dropouts due to toxicity. Overall, the adverse event rate in this trial was lower than that reported in trial of MM, perhaps related to the reduced frequency of bortezomib administration in our trial compared with the pivotal MM trials [29, 30] . After it was approved in 2003 for MM, there have been sporadic reports of patients who developed pulmonary toxicity while receiving bortezomib [17] [18] [19] . This raised concerns whether bortezomib would be safe in patients with compromised pulmonary function. With regard to pulmonary toxicity specifically, there were two pulmonary-related adverse events, which were grade 1 and 2, and neither caused a dropout from the study. Further our PFT data on MM patients suggests that there is no adverse impact of bortezomib on pulmonary function when it is administered for a prolonged period of time.
Our pilot trial was not designed or powered to show efficacy. Nevertheless, the data on FEV1 decline prior to the diagnosis of pulmonary CGVHD and after beginning bortezomib are encouraging. More than half the patients had improvement in their FEV1 slope and nearly all of them had an attenuation of FEV1 decline. It should be noted that since we did not have interim pulmonary function testing, we assumed a continuous decline in FEV1 from SCT to the time of pulmonary GVHD diagnosis. This may not be an accurate assumption as a recent study suggested that there is precipitous loss of FEV1 in the 6 months prior to pulmonary GVHD diagnosis [20] . Thus, if our patients' decline in FEV1 was predominantly in the 6 months prior to diagnosis, then the magnitude of FEV1 attenuation during bortezomib treatment would be much greater. Our SF-36 data are also consistent with stabilization of their disease. It should be noted that all of the patients were already on significant immunosuppression at the time of pulmonary CGVHD diagnosis and bortezomib was safe and tolerable on this background therapy.
There are limitations of our data that should be acknowledged. There was no control group and we cannot exclude the possibility that attenuation of FEV1 may have occurred spontaneously. In addition, the duration of the study was 10 weeks, which is relatively short and thus we cannot comment on long-term safety and tolerability data in this patient population. Previous data on the natural history of pulmonary GVHD reported that FEV1 decline in the 6 months following pulmonary CGVHD diagnosis was −0.86%/month for untreated patients. Our median decrease of −0.25%/month compares favorably and is consistent with disease attenuation. Our study suggests that bortezomib is safe over the short term and should be assessed in a longer-term study in which longer-term safety and efficacy outcomes could be assessed.
Conclusion
Bortezomib is safe and well tolerated in pulmonary GVHD patients with severely diminished FEV1 and is associated with improvement in FEV1 decline.
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